{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:15:38Z","timestamp":1776435338511,"version":"3.51.2"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.amjmed.2022.08.019","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T03:35:38Z","timestamp":1664422538000},"page":"96-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab\u2013Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center"],"prefix":"10.1016","volume":"136","author":[{"given":"Mohanad M.","family":"Al-Obaidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet B.","family":"Gungor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra E.","family":"Kurtin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann E.","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bekir","family":"Tanriover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9035-2952","authenticated-orcid":false,"given":"Tirdad T.","family":"Zangeneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2022.08.019_bib0001","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.17128","article-title":"Tixagevimab\/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave","author":"Al Jurdi","year":"2022","journal-title":"Am J Transplant"},{"issue":"23","key":"10.1016\/j.amjmed.2022.08.019_bib0002","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.amjmed.2022.08.019_bib0003","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Montgomery","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.amjmed.2022.08.019_bib0004","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s40265-022-01731-1","article-title":"Tixagevimab\u00a0+\u00a0cilgavimab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.amjmed.2022.08.019_bib0005","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.17121","article-title":"Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients","author":"Benotmane","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.amjmed.2022.08.019_bib0006","article-title":"Omicron BA.1 and BA.2 neutralizing activity following pre-exposure prophylaxis with tixagevimab plus cilgavimab in vaccinated solid organ transplant recipients","author":"Karaba","year":"2022","journal-title":"medRxiv"},{"issue":"27","key":"10.1016\/j.amjmed.2022.08.019_bib0007","doi-asserted-by":"crossref","first-page":"878","DOI":"10.15585\/mmwr.mm7127a3","article-title":"Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19 \u2013 COVID-NET, 10 States, March 2020\u2013February 2022","volume":"71","author":"Singson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.amjmed.2022.08.019_bib0008","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1038\/s41598-022-08559-5","article-title":"In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate","volume":"12","author":"Touret","year":"2022","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.amjmed.2022.08.019_bib0009","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccell.2022.05.007","article-title":"Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies","volume":"40","author":"Stuver","year":"2022","journal-title":"Cancer Cell"},{"issue":"7906","key":"10.1016\/j.amjmed.2022.08.019_bib0010","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"issue":"7898","key":"10.1016\/j.amjmed.2022.08.019_bib0011","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.amjmed.2022.08.019_bib0012","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMc2119407","article-title":"Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant","volume":"386","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2022.08.019_bib0013","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1093\/cid\/ciac143","article-title":"Omicron variant escapes therapeutic monoclonal antibodies (mAbs) including recently released Evusheld\u00ae, contrary to 8 prior main variant of concern (VOC)","volume":"75","author":"Boschi","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.amjmed.2022.08.019_bib0014","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.kint.2022.07.008","article-title":"Covid-19 morbidity decreases with tixagevimab\/cilgavimab preexposure prophylaxis in kidney transplant recipients non\/low vaccine responders","volume":"102","author":"Kaminski","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjmed.2022.08.019_bib0015","first-page":"ciac625","article-title":"Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality","author":"Kertes","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2022.08.019_bib0016","unstructured":"Arizona Department of Health Services. COVID-19 data. Available at: http:\/\/www.azdhs.gov\/covid19\/data\/index.php. Accessed July 14, 2022."},{"issue":"7","key":"10.1016\/j.amjmed.2022.08.019_bib0017","doi-asserted-by":"crossref","first-page":"ofac283","DOI":"10.1093\/ofid\/ofac283","article-title":"Characterization of early-onset severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients who received tixagevimab-cilgavimab prophylaxis","volume":"9","author":"Ordaya","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.amjmed.2022.08.019_bib0018","unstructured":"U.S. Food & Drug Administration (FDA). FDA authorizes revisions to Evusheld dosing. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-authorizes-revisions-evusheld-dosing. Accessed August 4, 2022."}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322006374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322006374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:30:12Z","timestamp":1757583012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934322006374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0002934322006374"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.08.019","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab\u2013Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}